Introducing Ivantis, a leading brand in the field of ophthalmology. Ivantis offers a range of innovative products and services to address various eye conditions, with a particular focus on glaucoma treatment. One of their standout products is Hydrus®, a microinvasive glaucoma surgery (MIGS) device that has revolutionized the treatment of mild to moderate primary open-angle glaucoma.

Made of highly flexible and biocompatible nitinol, the Hydrus® Microstent is roughly the size of an eyelash and works by restoring the flow of aqueous from the anterior chamber to Schlemm's canal. What sets Hydrus® apart is its unique mechanism of action. With its open-window scaffold design, the microstent precisely dilates and scaffolds Schlemm's canal, providing outflow pathways for aqueous and ensuring access to collector channels.

It is the only MIGS implant that spans approximately 90 degrees of Schlemm's canal. The outstanding clinical outcomes of Hydrus® have been demonstrated in a pivotal trial over a five-year period. The device has shown significant safety and effectiveness, with patients experiencing a 66% reduction in medications and a 55% relative reduction in incisional SSIs compared to cataract surgery alone.

Ivantis is committed to evidence-based outcomes and has received high recommendations from the American Academy of Ophthalmology. Their dedication to exceptional quality and patient care make them a trusted choice for ophthalmologists worldwide